Search for: "Teva Pharmaceuticals LLC" Results 81 - 100 of 253
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
17 Jul 2014, 10:58 am
USA; Accord Healthcare, Inc.; Intas Pharmaceuticals Ltd.; Amneal Pharmaceuticals LLC; Amneal Pharmaceuticals of New York, LLC; Amneal Pharmaceuticals Co. [read post]
2 Jan 2008, 9:05 pm
Baysaver Technologies, Inc. et al Teva Pharmaceuticals Industries Ltd. et al v. [read post]
17 Oct 2014, 5:09 pm by Oyez Project
Stephens Teva Pharmaceuticals USA, Inc., v. [read post]
1 Aug 2011, 8:19 am
The seven defendants, Actavis Elizabeth LLC, Sun Pharmaceuticals, Sandoz Inc., Mylan Pharmaceuticals, Apotex Inc., Aurobindo Pharma Ltd., and Teva Pharmaceuticals, had filed an Abbreviated New Drug Application (ANDA) seeking to utilize Lilly's patented formula and claiming invalidity of Lilly's patent, No. 5,658,590, Treatment of attention-deficit/hyperactivity disorder, which has been issued by the US Patent Office. [read post]
17 Mar 2014, 11:03 am
.; Intas Pharmaceuticals Ltd.; Amneal Pharmaceuticals LLC; Amneal Pharmaceuticals of New York, LLC; Amneal Pharmaceuticals Co. [read post]
30 Jun 2014, 10:28 am
USA; Accord Healthcare, Inc.; Intas Pharmaceuticals Ltd.; Amneal Pharmaceuticals LLC; Amneal Pharmaceuticals of New York, LLC; Amneal Pharmaceuticals Co. [read post]
17 Sep 2018, 6:48 am by Law Offices of Jeffrey S. Glassman
Current drugs subject to recall include: Tablets sold by firms AvKare (Teva/Actavis) and (Hetero/Camber), A-S Medication Solutions LLC (Teva/Actavis & Prinston/Solco), Bryant Ranch Prepack Inc, (Teva/Actavis), Hetero Labs (labeled as Camber Pharmaceuticals Inc.), H J Harkins Co., Northwind Pharmaceuticals (Teva/Actavis), NuCare Pharmaceuticals Inc. [read post]
23 Jul 2018, 12:05 pm by Dennis Crouch
Teva Pharmaceuticals USA, Inc., et al., No. 17-1229. [read post]
17 Oct 2023, 3:40 pm by Rik Lambers (Brinkhof)
Teva was issues a Dutch marketing authorisation for a generic version of Nebido with the brand name Testosterone Teva in December 2022. [read post]
13 Jun 2017, 12:00 pm by Sheppard Mullin
Teva Pharmaceuticals USA, Inc., the Federal Circuit had its first opportunity to address the impact of the “or otherwise available to the public” clause contained in post-AIA 35 U.S.C. [read post]
13 Jun 2017, 12:00 pm by Daniel Taskalis
Teva Pharmaceuticals USA, Inc., the Federal Circuit had its first opportunity to address the impact of the “or otherwise available to the public” clause contained in post-AIA 35 U.S.C. [read post]
8 Jun 2017, 3:27 am
Teva Pharmaceuticals USA, Inc., the Federal Circuit had its first opportunity to address the impact of the “or otherwise available to the public” clause contained in post-AIA 35 U.S.C. [read post]